-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING CORPORATION - FIRST PATIENT DOSING IN ATEBIMETINIB PHASE 2 TRIAL EXPECTED MID-2027

Reuters·11/12/2026 12:30:01

Please log in to view news